Чихладзе Н. М., Чазова И. Е. Возможности применения комбинированной терапии верапамилом СР и трандолаприлом у больных артериальной гипертонией в группах высокого риска. Кардиоваскулярная терапия и профилактика. 2007;6(8):99-105.
1. Zannad F, Matzinger A, Larche J. Trough/peak ratios of once daily angiotensin converting enzyme inhibitors and calcium antagonists. AJH 1996; 9: 633-43.
2. Messerli F, Frishman WH, Elliot WJ for the Trandolapril Study Group. Effects of verapamil and trandolapril in the treatment of hypertension. Am J Hypertens 1998; 11: 633-43.
3. Сonzalez RF, de la Figuera M, Rodriguez GAS. Duration of Trandolapril antihypertensive effects after 24 and 48 hours from the last dose THOR study. Clin Drug Invest 1999; 17 (1): 43-50.
4. Viskoper Rg, Compagnone D, Dies R, Zilles P. Verapamil and trandolapril alone and in fixed combination in moderate essential hypertension: a multicenter, double-masked study. Current Ther Res 1997; 58 (6): 331-42.
5. Viskoper Rg, Compagnone D, Dies R, Zilles P. Verapamil and trandolapril alone and in fixed combination on 24-hour ambulatory blood pressure profiles of patients with moderate essential hypertension. Current Ther Res 1997; 58 (6): 343-51.
6. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003; 290: 2805-16.
7. Hennekens CH, Albert CM, Godfried SL, et al. Adjuncitve drug therapy for acute myocardial infaction – evidence from clinical trials. N Eng J Med 1996; 335: 1660-7.
8. Hansen JF, Hagerup L, Sigurd B, et al. Cardiac event rates after acute myocardial infarction in patient treated with verapamil and trandolapril versus trandolapril alone. Am L Cardiol 1997; 79: 738-41.
9. Lefrandt JD, Heitmann J, Sevre K, et al. The effects of dihydropyridine and phenylalkylamine calcium antagonist on autonomic function in hypertension: the VAMPHYRE Study. AJH 2001; 14: 1083-9.
10. Marcus R, Krause L, Weder AB, et al. Sex-specific determinants of increased left ventricular mass in the Tecumseh Blood Pressure Study. Circulation 1994; 90: 928-36.
11. Palatini P, Julius S. Association of tachycardia with morbidity and mortality: pathophysiological considerations. J Hum Hypertents 1997; 11 (Suppl 1): S19-27.
12. Schwartz PJ, La Rovere MT, Vanoli E. Autonomic nervous system and sudden cardiac death: Experimental basis and clinical observations for post-myocardial infarction risk stratification. Circulation 1992; 85: 177-91.
13. Torp-Pedersen C and Kober L for the TRACE Study Group. Effect of ACE inhibitor trandolapril on life expectancy of patients with reduced left-ventricular function after acute myocardial infarction. Lancet 1999; 354: 9-12.
14. Kober L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular disfunction after myocardial infarction. N Engl J Med 1995; 333: 1670-6.
15. Fernandez R, Puig JG, Rodriguez-Perez JC, et al. Effects of two antihypertensive combinations on metabolic control in type-2 diabetic hypertensive patients with albuminuria: a randomized, double-blind study. J Human Hypertens 2001; 15: 849-56.
16. Bakris G, Molith M, Hewkin N, et al. Differences in glucouse tolersnce between fixed dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care 2006; 29: 2592-7.
17. Eurich DT, Majumdar SR, Tsuyuki RT, Johnson JA. Reduced mortality associated with the use of ACE inhibitors in patients with type 2 diabetes. Diabetes Care 2004; 27: 1330-4.
18. Parving HH, Mauer M, Ritz E. Diabetic nephropathy. In: Brenner BM, ed. Brenner & Rector’s The kidney. 7th ed. Vol. 2. Philadelphia: Saunders 2004: 1777-818.
19. Adler AI, Stevens RJ, Manley SE, et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003; 63: 225-32.
20. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 1984; 310: 356-60.
21. Nelson RG, Knowler WC, Prettitt DJ, et al. Assessing risk of overt nephropathy in diabetic patients from albumin excretion in untimed urine specimens. Arch Intern Med 1991; 151: 1761-5.
22. Ruggenenti P, Fassi A. Ilieva AP, et al. Preventing Microalbuminuria in type 2 diabetes. N Eng J Med 2004; 351 (19): 1941-51.
23. Bakris GL. Weir MR, DeQuattro V, Mc Mahon FY. Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int 1998; 54 (4): 1283-9.
24. The PROCOPA study Group. Dissociation between blood pressure reduction and fall in proteinuria in primary renal disease: a randomised double-blind trial. J Hypertens 2002; 20: 729-37.
